PHIO vs. RVPH, XLO, ATNM, SPRO, OSTX, IRD, RNTX, STTK, HOWL, and SCYX
Should you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Reviva Pharmaceuticals (RVPH), Xilio Therapeutics (XLO), Actinium Pharmaceuticals (ATNM), Spero Therapeutics (SPRO), OS Therapies (OSTX), Opus Genetics (IRD), Rein Therapeutics (RNTX), Shattuck Labs (STTK), Werewolf Therapeutics (HOWL), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry.
Phio Pharmaceuticals vs.
Reviva Pharmaceuticals (NASDAQ:RVPH) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.
Reviva Pharmaceuticals' return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.
Phio Pharmaceuticals received 9 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 90.63% of users gave Reviva Pharmaceuticals an outperform vote while only 64.41% of users gave Phio Pharmaceuticals an outperform vote.
Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 27.2% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Reviva Pharmaceuticals had 4 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 6 mentions for Reviva Pharmaceuticals and 2 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 0.72 beat Reviva Pharmaceuticals' score of 0.15 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.
Reviva Pharmaceuticals has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.
Reviva Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 1,023.60%. Phio Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 108.33%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Reviva Pharmaceuticals is more favorable than Phio Pharmaceuticals.
Summary
Reviva Pharmaceuticals beats Phio Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Phio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phio Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:PHIO) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy PHIO Stock Free PHIO Stock Alerts